Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

"Jumping Gene" Diminishes The Effect Of A New Type 2 Diabetes Risk Gene
Research led by the German Institute of Human Nutrition (DIfE) has identified a new gene associated with diabetes, together with a mechanism that makes obese mice less susceptible to diabetes. A genomic fragment that occurs naturally in some mouse strains diminishes the activity of the risk gene Zfp69. The researchers also found that the corresponding human gene (ZNF642) is especially active in overweight individuals with diabetes. The results of the study, which also involved scientists from the University of Leipzig and the German Cancer Research Center in Heidelberg, are published July 3 in the open-access journal PLoS Genetics.

Study Reveals Prevalence Of Disordered Eating In Patients With Anxiety
Doctors and other health workers should be more aware of the high risk of eating disorders among people with obsessive compulsive disorder (OCD) and other anxiety disorders.
News of the day
Dialing Up The Degrees To Fight Cancer
"My wish is simple, but I wouldn"t have given it a second thought this time last year," Joe Castelli said as his eyes welled up with tears. "I want to see my children grow up. I have two daughters who are nine and seven."
Endocrinology

Onset Therapeutics Launches HYLATOPIC™ Emollient Foam For Atopic Dermatitis

Onset Therapeutics, a specialty pharmaceutical company focused in dermatology, announced the FDA approval and commercial launch of HYLATOPIC™ Emollient Foam, a unique, non-steroidal prescription product indicated to manage and relieve the burning, itching and pain experienced with various types of dermatoses, including atopic dermatitis, allergic contact dermatitis and radiation dermatitis. HYLATOPIC™ Emollient Foam is formulated to rapidly hydrate the stratum corneum, the top layer of the skin, and immediately provide a semi-permeable barrier that protects against irritants and excessive water loss through the epidermis. HYLATOPIC™ is clinically proven to rapidly increase skin hydration and reduce transepidermal water loss1, supporting the skin"s natural recovery from skin barrier dysfunction to optimize therapeutic outcomes. HYLATOPIC™ is safe and easy to spread over large areas and therefore is ideal for atopic dermatitis patients with disease coverage on greater than 10% body surface area (BSA). The Company"s recent market research with dermatologists indicates that 70% or more of their patients may have atopic dermatitis present on at least 10% of their body. Developed with the Company"s DELEVO™ Foam Technology, HYLATOPIC™ is cosmetically elegant, contains no drying alcohols, is absorbed rapidly, and leaves no oily or sticky residue. "We are very excited to be able to offer HYLATOPIC™ to our physicians and patients," states Michael Heffernan, President of Onset Therapeutics. "It is well known that skin barrier dysfunction is a fundamental problem in atopic dermatitis patients. HYLATOPIC"s 3-step approach to hydrate, protect and restore the natural skin barrier, combined with the aesthetic and safety elements which drive compliance, assists in helping our physicians achieve the best therapeutic outcomes." HYLATOPIC™ Emollient Foam is currently available through all major drug wholesalers. About Atopic Dermatitis Atopic dermatitis is a disease characterized by dry, cracked, itchy, and inflamed skin, often presenting on greater than 10% of the body surface area. It accounts for 10-20% of all Dermatology visits2 and affects approximately 3% of the US population2, 90% of whom develop symptoms by age 53. The compromised skin barrier in atopic dermatitis patients allows excessive water loss through the epidermal layer of the skin and penetration of potential allergens. About Onset Therapeutics Onset Therapeutics is a specialty pharmaceutical company focused on the development and commercialization of dermatology products formulated with the Company"s innovative proprietary topical formulation technologies and unique delivery systems. The Company utilizes its novel DELEVO™ Foam Technology that is designed to deliver enhanced penetration of proven active ingredients in cosmetically elegant, hydrating formulations with the goal of enhancing patient compliance. For more information, please visit the company"s website at http://www.onsettx.com. References: 1. Data on File Collegium Pharmaceutical 2. National Institute of Arthritis and Musculoskeletal and Skin Diseases. Available at: http://www.niams.nih.gov/hi/topics/dermatitis/index.html. 3. Rudikoff D, Lebwohl M. Atopic dermatitis. Lancet. 1998;351:1715-1721. Onset Therapeutics


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009